Financial Data and Key Metrics Changes - In Q4 2025, RxSight reported sales of $32.6 million, a decrease of 19% year-over-year due to lower LDD sales [7] - The company sold 25 LDD units globally in Q4 2025, generating $3 million in revenue, compared to 83 units and $11 million in the same period last year [7][8] - LAL sales were 28,611 units, down 2% year-over-year but up 10% sequentially, contributing $28.2 million to total sales, which accounted for 86% of total company sales in Q4 2025, up from 71% a year ago [9] - Gross margin improved to 77.5% in Q4 2025 from 71.6% in the prior year [10] - The net loss for Q4 2025 was $9.2 million, or $0.22 per share, compared to a net loss of $27.5 million, or $0.71 per share in 2024 [11][14] Business Line Data and Key Metrics Changes - LDD revenue decreased by 48% year-over-year, while LAL sales increased by 12% [12] - The full-year gross profit margin for 2025 was 76.6%, up from 70.7% in 2024, driven by a higher mix of LAL revenue [13] - Total operating expenses for 2025 were $151.2 million, an increase of 11% compared to 2024, primarily due to higher personnel costs and investments in R&D and commercial activities [13] Market Data and Key Metrics Changes - The company anticipates a full-year revenue guidance for 2026 of $120 million to $135 million, implying a year-over-year decline of approximately 5% at the midpoint [15] - The company expects Q1 2026 sales to be the lowest due to seasonality and challenging comparisons from the previous year [16] - International sales are expected to contribute modestly in 2026, focusing on building relationships with key opinion leaders and collecting clinical data for future growth [17] Company Strategy and Development Direction - RxSight aims to improve utilization within its existing installed base through targeted practice engagement and education initiatives [25] - The company is taking a disciplined approach to capital placements to ensure sustainable execution and superior clinical outcomes [25] - RxSight is focused on expanding its international presence methodically, with plans for more meaningful sales in 2027 and beyond [17][33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 financial results were below expectations but highlighted meaningful progress in advancing LAL technology [21] - The company is encouraged by early signs of improvement in procedure volumes and is committed to delivering consistent performance over time [35] - Management remains realistic about the challenges ahead but believes the foundation is in place for future growth [36] Other Important Information - The company ended 2025 with no debt and approximately $228 million in cash equivalents and short-term investments [14] - Stock-based compensation for Q4 2025 was $7.8 million, leading to an adjusted net loss of $1.3 million [11] Q&A Session Summary Question: What is the underlying health of the market for LALs and LDDs in 2026? - Management noted an uptick in Q4 and hopes for continued improvement in 2026, with guidance reflecting these trends [40][41] Question: What are the expectations for LDD placements and LAL growth? - The company expects LDD placements to slightly accelerate from the 2025 exit rate, with LAL growth anticipated in the low single-digit range [49][50] Question: How long will manufacturing variances impact gross margin? - Management indicated that they expect to work through lower-cost inventory over the year, with gross margins improving in the second half [52][55] Question: What is the strategy for international market expansion? - The company is focused on developing key opinion leaders and clinical data in international markets, with a goal of leveraging learnings from North America [82] Question: How is the competitive environment factored into 2026? - Management monitors competition closely and anticipates new product launches but believes that over time, the market will return to baseline [62]

Financial Data and Key Metrics Changes - In Q4 2025, RxSight reported sales of $32.6 million, a decrease of 19% year-over-year due to lower LDD sales, with LDD placements dropping from 83 units to 25 units globally [5][6] - Full year 2025 sales totaled $134.5 million, reflecting a 4% increase year-over-year, despite a 48% decrease in LDD revenue, which was partially offset by a 12% increase in LAL sales [8][9] - The gross profit margin for 2025 was 76.6%, up from 70.7% in 2024, driven by a higher mix of LAL revenue [9] - The company reported a net loss of $38.9 million for 2025, compared to a net loss of $27.5 million in 2024 [9] Business Line Data and Key Metrics Changes - LDD revenue in Q4 2025 was $3 million, down from $11 million in the same period last year, while LAL sales accounted for 86% of total company sales, up from 71% year-over-year [6][7] - The company sold 28,611 LALs in Q4 2025, a 2% decrease from the previous year but a 10% increase sequentially [7] Market Data and Key Metrics Changes - The company anticipates a year-over-year decline in revenue for 2026, with guidance set at $120 million to $135 million, primarily due to lower LDD sales [10] - The international market is expected to contribute modestly to sales in 2026, with a focus on building relationships with key opinion leaders and collecting clinical data for future growth [11][19] Company Strategy and Development Direction - RxSight aims to improve utilization within its existing installed base through targeted practice engagement and education initiatives, while expanding access to technology in a measured way [16][20] - The company is focused on advancing its LAL technology and has received approximately 20 FDA approvals in support of product development over the past five years [18][19] - RxSight is building a foundation for long-term success in international markets, with a focus on developing key opinion leaders and clinical data [19][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 financial results were below expectations but highlighted meaningful progress in advancing LAL technology and improving clinical outcomes [13][14] - The company is optimistic about the potential for growth in the second half of 2026 as commercial initiatives begin to gain traction [10][22] Other Important Information - The company ended 2025 with no debt and approximately $228 million in cash equivalents and short-term investments [9] - Gross margin guidance for 2026 is set at 70%-72%, reflecting a prudent view due to the sell-through of higher-cost inventory [11][12] Q&A Session Summary Question: What are the underlying health trends for LALs and LDDs in 2026? - Management noted an uptick in Q4 2025 and hopes this trend continues into 2026, with guidance reflecting these potential improvements [24][25] Question: What is the expected decline in LDD placements for 2026? - The company expects a slight acceleration in LDD placements, with Q1 anticipated to be the lowest quarter [30][31] Question: How long will manufacturing variances impact gross margin? - Management indicated that the impact of higher-cost inventory will be felt throughout 2026, but they expect improvements as the year progresses [34][37] Question: What is the competitive landscape for 2026? - Management is monitoring the competitive environment closely, noting that new product launches tend to be episodic and transient [45][46] Question: What is the go-to-market strategy for international expansion? - The company is focused on developing key opinion leaders and clinical data in international markets, leveraging learnings from North America [64][66]

Financial Data and Key Metrics Changes - In Q4 2025, RxSight reported sales of $32.6 million, a decrease of 19% year-over-year due to lower LDD sales, with LDD revenue contributing only $3 million compared to $11 million in the previous year [5][8] - Full year 2025 sales totaled $134.5 million, reflecting a 4% increase year-over-year, despite a 48% decrease in LDD revenue, which was partially offset by a 12% increase in LAL sales [8][9] - The gross profit margin for 2025 was 76.6%, up from 70.7% in 2024, primarily driven by a higher mix of LAL revenue [9] - The company reported a net loss of $38.9 million for 2025, compared to a net loss of $27.5 million in 2024 [9] Business Line Data and Key Metrics Changes - LDD sales saw a significant decline, with only 25 units sold in Q4 2025 compared to 83 units in the same period last year [5] - LAL sales were 28,611 units in Q4 2025, down 2% year-over-year but up 10% sequentially, accounting for 86% of total company sales, an increase from 71% in the previous year [6] - The gross margin for LALs improved to 77.5% in Q4 2025, compared to 71.6% in the year-ago period [6] Market Data and Key Metrics Changes - The company anticipates a relatively small contribution from international sales in 2026, focusing on building relationships with key opinion leaders and collecting clinical data for future growth [11] - The premium IOL market is expected to continue growing, driven by younger demographics seeking cataract surgery and a preference for high-quality vision [52] Company Strategy and Development Direction - RxSight aims to improve utilization within its existing installed base through targeted practice engagement and education initiatives, while expanding access to technology through disciplined LDD placements [15][16] - The company is committed to advancing its LAL technology and has received approximately 20 FDA approvals in support of product development over the past five years [18] - RxSight is focusing on international expansion, particularly in Europe, Asia, and Australia, to build a foundation for long-term success [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 financial results were below expectations but highlighted meaningful progress in advancing LAL technology and improving clinical outcomes [13] - The company is optimistic about the potential for growth in 2026, with expectations for a rebound in sales in the second half of the year as commercial initiatives gain traction [10][21] - Management remains realistic about the challenges ahead but is focused on delivering consistent performance over time [20] Other Important Information - The company ended 2025 with no debt and approximately $228 million in cash equivalents and short-term investments [10] - Full-year revenue guidance for 2026 is set at $120 million to $135 million, implying a year-over-year decline at the midpoint of the range [10] Q&A Session Summary Question: What is the underlying health of the market for LALs and LDDs in 2026? - Management noted an uptick in Q4 2025 and hopes this trend continues into 2026, with guidance reflecting these potential improvements [24][25] Question: What are the assumptions for LDD placements and LAL growth in 2026? - The company expects LDD placements to slightly accelerate from the 2025 exit rate, with LAL growth anticipated in the low single-digit range [31][32] Question: How long will manufacturing variances impact gross margins? - Management indicated that they expect to work through lower-cost inventory over the course of 2026, with gross margins stabilizing in the second half of the year [34][37] Question: What is the competitive environment like for 2026? - Management is monitoring the competitive landscape, noting that while new product launches may occur, they tend to be transient and lead to a return to baseline over time [45][46] Question: What is the go-to-market strategy for international expansion? - The company is focused on developing key opinion leaders and clinical data in international markets, leveraging learnings from North America [64][66]

Product Innovation and Technology - The RxSight system is the first commercially available premium cataract technology that allows for customized visual acuity adjustments post-surgery, addressing limitations of conventional IOLs [25]. - The RxSight system allows for adjustments in spherical and cylindrical refraction in 0.25 diopter increments, unlike fixed-power lenses of other premium IOLs [30]. - The proprietary technology of the RxSight system is based on photochemistry, allowing for post-operative adjustability of the LAL through UV light exposure [54]. - The LAL is made from a proprietary silicone formulation that optimizes mechanical and optical properties to improve vision outcomes following cataract surgery [55]. - The RxSight system's LDD uses proprietary software to deliver UV light treatments in a predefined pattern, allowing for adjustments in 0.25 diopter increments, similar to traditional refractive procedures [59]. - The RxSight system allows for postoperative customization, enabling patients to preview and compare possible vision outcomes based on their unique preferences and lifestyle requirements [66]. - The RxSight Light Adjustable Lens (LAL) does not induce higher rates of glare and halos compared to monofocal IOLs, addressing common side effects associated with multifocal IOLs [66]. Market Overview and Growth Projections - In the U.S., premium IOL procedures represented about 21% of all cataract procedures in 2025, generating approximately $860 million in revenue, projected to grow at an 8.0% CAGR by 2030 [28]. - The global premium IOL revenue was approximately $2.6 billion in 2025, expected to grow at an 11% CAGR through 2030 [45]. - The number of cataract procedures globally is projected to grow at a CAGR of 3.4% to over 39 million by 2030, with U.S. procedures expected to grow at a CAGR of 3.2% to 6.1 million by 2030 [45]. - The premium cataract surgery market remains underpenetrated due to doctors' reluctance to recommend premium IOLs and patients' confusion regarding trade-offs [29]. Clinical Outcomes and Patient Satisfaction - In FDA clinical trials, 70% of LAL patients achieved 20/20 or better uncorrected visual acuity without glasses, compared to about 40% for other premium IOLs [30]. - The RxSight system achieved a 70.1% rate of eyes with 20/20 or better uncorrected distance visual acuity, significantly outperforming Alcon's Acrysof Toric (38.4%) and J&J's Tecnis Toric (43.6%) in pivotal studies [66]. - In a 2025 customer survey, 90% of respondents believed the RxSight system delivered the highest quality vision, and 96% would recommend the LAL to others [36]. - A recent post-approval study showed that 82.5% of LAL eyes achieved 20/20 or better uncorrected distance visual acuity, compared to 50.6% for control eyes [69]. Regulatory and Compliance Challenges - The FDA regulates product design, testing, and marketing, which can be resource-intensive and lengthy for new medical devices [101]. - The PMA approval process for Class III medical devices is generally more costly and time-consuming than the 510(k) process, requiring extensive technical information and clinical trial data [106]. - The FDA may require post-approval studies or post-market surveillance for devices, especially for those classified as high-risk, to ensure ongoing safety and effectiveness [122]. - The company is subject to periodic unscheduled inspections by the FDA, which could result in significant penalties for non-compliance [131]. Financial Performance and Projections - For the years ended December 31, 2025 and 2024, the company reported losses from operations of $48.2 million and $36.9 million, respectively, resulting in an accumulated deficit of $661.0 million as of December 31, 2025 [167]. - The company expects to continue incurring significant sales and marketing, research and development, and regulatory expenses as it expands its marketing efforts and seeks regulatory approvals for future products [167]. - As of December 31, 2025, the company had $228.1 million in cash, cash equivalents, and short-term investments, which is anticipated to meet cash needs for at least 12 months [173]. - The company has a history of net losses and expects to continue incurring losses in the future, making it essential to generate significant additional revenue to achieve and sustain profitability [168]. Competitive Landscape - The global cataract IOL market is highly concentrated, with Alcon and Johnson & Johnson accounting for approximately 75% of the U.S. premium cataract surgery market [97]. - The IOL market is highly competitive, with significant players like Alcon and Johnson & Johnson, which may hinder the company's market penetration [192]. - The company faces intense competition in the surgical ophthalmology market, primarily driven by technological innovation and regulatory approval [97]. Operational Risks and Challenges - The company relies on third-party suppliers for manufacturing components of the RxSight system, making it vulnerable to supply disruptions [160]. - The company operates in five separate facilities in California, with no redundant facilities, making it vulnerable to significant operational disruptions due to natural disasters [196]. - Changes in healthcare policy could significantly reduce revenues from product sales due to potential limitations on coverage and reimbursement [138]. - The company faces significant cybersecurity risks due to potential vulnerabilities in its internal and third-party systems, which could lead to unauthorized access or data breaches [212]. Strategic Initiatives and Future Plans - The company plans to continue expanding its sales and marketing infrastructure to increase its customer base and grow its business [161]. - The company intends to grow by developing and commercializing additional products through research and development or by acquiring technologies from third parties [220]. - The company is focused on converting high-volume premium cataract surgeons to the RxSight system to increase market penetration [67].

Core Insights - RxSight, Inc. reported a decrease in total revenue for the fiscal year 2025, with global sales of $134.5 million, down 4% from the previous year, primarily due to a significant drop in Light Delivery Device (LDD) system sales, which decreased by 48% compared to 2024 [4][6] - The company experienced a 12% growth in Light Adjustable Lens (LAL) revenue, indicating strong adoption among physicians and patients [4][6] - Operating expenses increased by 11% to $151.2 million, driven by strategic investments in commercial and operational expansion, as well as research and development [5][6] Financial Performance - For the fourth quarter of 2025, total revenue was $32.6 million, a 19% decrease from $40.2 million in Q4 2024, largely due to lower LDD revenue [7][11] - Gross profit for the fourth quarter was $25.3 million, representing 77.5% of revenue, a decrease from 71.6% in the same quarter of the previous year [8] - The net loss for the full year 2025 was $(38.9) million, or $(0.95) per share, compared to a net loss of $(27.5) million, or $(0.71) per share in 2024 [6][11] Unit Sales and Market Position - In 2025, unit sales of LAL increased by 12% to 109,615, while LDD unit sales dropped by 47% [9][12] - The installed base of LDD expanded to 1,134, providing a foundation for future procedure growth [9] - Over 300,000 RxSight LAL procedures have been performed since the product launch, highlighting its clinical benefits [9] Strategic Developments - The company has received regulatory approvals for the RxSight system in multiple regions, including North America, Europe, Singapore, South Korea, and Australia, enhancing its international market opportunities [5][9] - RxSight's FDA post-approval study results demonstrating superior outcomes for LAL eyes compared to traditional toric IOLs have been accepted for publication, reinforcing the product's clinical value [9] 2026 Financial Guidance - The company provided guidance for 2026, projecting revenue between $120.0 million and $135.0 million, with expected gross margins of 70% to 72% [16]

Core Viewpoint - RxSight, Inc. will report its financial results for Q4 and full year 2025 on February 25, 2026, with a conference call scheduled for discussion of these results [1]. Company Overview - RxSight, Inc. is an ophthalmic medical device company focused on providing high-quality customized vision for patients post-cataract surgery [3]. - The company offers the RxSight® Light Adjustable Lens system, which is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing for customization of vision quality [3]. Conference Call Details - The conference call to discuss financial results can be accessed by dialing (800) 715-9871 or (646) 307-1963, with a conference code of 3406720 [2]. - The call will also be available in listen-only mode via the company's investor relations website, with an archived recording accessible shortly after the call [2].

Company Overview - RxSight, Inc. (NASDAQ:RXST) was founded in 1997 and is based in Aliso Viejo, California, specializing in adjustable intraocular lenses for cataract surgery, enabling post-operative vision correction [4] Financial Performance - During its third-quarter 2025 earnings call, RxSight narrowed its full-year revenue guidance to a range of $125 million to $130 million, an increase from the previous guidance of $120 million to $130 million [3] - The company highlighted ongoing progress in its international rollout, particularly in Asia and Europe, supported by regulatory approvals and investments in commercial infrastructure [3] Market Analysis - William Blair initiated coverage of RxSight with a Market Perform rating and no price target, citing stalled sales growth in 2025 after strong adoption from early users between 2021 and 2024 [1] - The firm noted that evidence of sustained commercial reacceleration is necessary, despite the stock trading at a discount to peers [1]

Company Overview - RxSight is focused on transforming cataract surgery outcomes through a new capability called adjustability, which has not previously existed in ophthalmology [2] - The company has grown to approximately 500 employees and has performed around 300,000 Light Adjustable Lens (LAL) procedures [3] Market Position - RxSight operates in about 1,100 ophthalmic offices and has trained over 2,500 surgeons [3] - The company has achieved a market share of approximately 10% in the U.S. premium intraocular lens (IOL) market [3] Recent Performance - RxSight reported a 12% year-over-year growth in procedures and a nearly 20% increase in its installed base [4] - The company announced the appointment of a new Chief Financial Officer, Mark Wilterding, who brings extensive experience in med tech and banking [4]

Summary of RxSight FY Conference Call (January 13, 2026) Company Overview - **Company**: RxSight (NasdaqGM:RXST) - **Industry**: MedTech, specifically focusing on ophthalmology and cataract surgery - **Key Product**: Light Adjustable Lens (LAL), a premium intraocular lens (IOL) that allows for post-operative adjustments to improve visual outcomes Core Points and Arguments - **Growth Metrics**: - RxSight has grown to approximately 500 employees and performed around 300,000 LAL procedures - The company has a market share of about 10% in the U.S. premium IOL market [4][39] - Achieved 12% year-over-year growth in procedures and nearly 20% increase in installed base [5][13] - **Market Dynamics**: - The U.S. sees about 5 million cataract surgeries annually, with a shift towards premium IOLs that offer enhanced services for patients willing to pay extra [7][8] - The premium IOL market is characterized by two main types: toric (astigmatism-correcting) and presbyopia-correcting lenses [8] - **Adjustability Technology**: - Introduced the concept of adjustability in cataract surgery, allowing for personalized lens adjustments post-surgery [9][10] - Over 90% of patients report high refractive accuracy with LAL, and 90% of doctors believe it provides the highest quality of vision [11][12] - **Financial Performance**: - Pre-announced fourth-quarter sales at $32.6 million, exceeding expectations [18] - Each LAL procedure generates approximately $2,000 in additional revenue for practices [12] - **Future Growth Strategies**: - Focus on increasing same-store sales and expanding the number of surgeons using LAL technology [13][19] - Plans to place more Light Delivery Devices (LDD) in additional practices, currently servicing only 25% of U.S. cataract surgeons [13][14] - **International Expansion**: - The company is targeting major markets in Asia and Europe, where 80% of premium procedures occur [15][42] - Initial commercialization efforts have begun in countries like Korea and Canada, with plans for further expansion [43][44] - **Market Positioning**: - RxSight is positioned as the third largest premium IOL provider in the U.S., with a long runway for growth [37] - The company believes adjustability will become a dominant feature in the premium IOL market, despite potential competition [40][41] Additional Important Insights - **Operational Challenges**: - The rapid growth led to some operational challenges in supporting a large installed base, which the company is addressing through improved customer support and training [28][30] - **Cash Position**: - Ended the year with approximately $225 million in cash, providing a strong financial position to support growth initiatives [47] - **Reimbursement Landscape**: - While the cost-effectiveness of LAL is favorable, expanding reimbursement from Medicare and insurers for cataract procedures is unlikely [52][53] This summary encapsulates the key points discussed during the conference call, highlighting RxSight's growth, market dynamics, and strategic initiatives moving forward.

Company Overview - RxSight, Inc. (RXST) shares increased by 14.1% to $10.09 in the last trading session, following a significant volume of shares traded, contrasting with a 30% loss over the previous four weeks [1][2] Financial Performance - The company is expected to report a quarterly loss of $0.25 per share, reflecting a year-over-year decline of 933.3%. Revenue is anticipated to be $26.91 million, down 33.1% from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Management Changes - Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, which may influence investor sentiment positively [2] Industry Context - RxSight operates within the Zacks Medical - Instruments industry, where IDEXX Laboratories (IDXX) also resides. IDXX shares increased by 1.6% to $724.76, with a 1.3% return over the past month [4]